Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Predicting Cancer’s Next Move

Published: Monday, November 11, 2013
Last Updated: Monday, November 11, 2013
Bookmark and Share
Research offers a new approach to studying drug resistance in cancer.

The approach helped them identify which biological pathways could be enabling melanoma to circumvent available anti-cancer treatments. Targeting the output of these pathways for treatment could potentially hinder the course of this often-fatal disease.

The researchers initiated the study to address a vexing clinical problem: on the rare occasions that drug treatments are found that effectively inhibit tumor growth, that success is often short-lived. As resistance mechanisms emerge, the therapies cease being effective and the tumors return.

Such is the case in melanoma. Roughly 50% of these cancers have been traced to a mutation in BRAF, a gene responsible for directing cell growth. Only a few years ago, drugs were developed that disrupt parts of the biological pathway that leads the mutation to spur unchecked growth in skin cells. Patients who have received the treatment have seen their tumors disappear – only to return an average of nine months later. Garraway's team, which includes researchers from the Broad Institute and Dana-Farber Cancer Institute, wanted to find out in a comprehensive fashion what mechanisms might be involved in the development of drug resistance in these cases.

To find out, the team systematically mimicked gene activation by expressing over 15,000 genes to test their role in drug resistance. (For scale, the human genome contains approximately 20,000 genes.) This large-scale screen was conducted using the Open Reading Frame (ORF) gene expression library developed by the Broad's RNAi Platform and Dana-Farber’s Center for Cancer Systems Biology. ORFs are pieces of genetic material that researchers can use to "turn on" specific genes in order to investigate their function.

The team used the ORF library to activate each of the 15,000 genes individually in a cell line generated from a BRAF mutant melanoma tumor. The cells were then treated with drugs commonly used to combat this form of cancer, and the results were confirmed in seven additional BRAF mutant melanoma cell lines.

"Each time we expressed a gene, we asked, 'Does this change the sensitivity of this cell line to these drugs?” explained Cory Johannessen, a postdoctoral researcher in Garraway’s lab and the paper’s first author. “Observing each response gave us a picture of what the landscape of resistance mechanisms looked like for this particular type of melanoma."

This systematic approach turned up a comprehensive list of mechanisms that could possibly play a role in the development of drug resistance. The team then looked for patterns in their data and found that they could, in fact, identify commonalities – entire signaling pathways or networks – from the functional information derived from their approach.

One of the team’s most promising findings was also one of the most surprising: a central pathway contributing to drug resistance in BRAF mutant melanoma is one that oversees an aspect of normal skin development.

"It turns out that the pathway that's causing the resistance isn't random,” Johannessen said. “It's a pathway that is essential to skin cell biology; it's critical to the development of those cells and their sustained growth."

One critical component of normal skin is a type of cell known as melanocytes; these cells create skin pigment and protect the body from damage from the sun’s UV rays. In contrast to the normal course of melanocyte development, the melanocyte development pathway is turned off in BRAF mutant melanoma, and a pathway triggered by the BRAF mutation takes over. Instead of producing normal melanocytes, the BRAF mutation causes a chain of events that leads to the activation of a group of proteins (known as “transcription factors”) that tell cells to reproduce uncontrollably, forming cancerous tumors.

Current treatments for BRAF mutant melanoma target the chain of events that lead to the activation of these transcription factors, not the transcription factors, themselves – and that approach is successful for a time. The drugs disrupt the cancerous pathway, presenting an opportunity for the normal melanocyte development pathway to be turned back on. However, as the team discovered, if the melanocyte pathway is turned back on, it activates the same cancer-causing transcription factors previously controlled by the BRAF mutation. Once those transcription factors are activated, melanoma returns.

Johannessen said that they don’t yet know why these formerly healthy melanocyte pathways start producing the aberrant transcription factors. Nevertheless, knowing that the transcription factors are involved in drug resistance provides a new target for therapeutics.

While transcription factors have traditionally been viewed as “impossible” to target, the team suspected that they could hit them indirectly using chromatin-based therapeutics that are currently in clinical trials. These therapeutics target gene-regulating proteins in chromatin, which is one part of the cellular machinery that controls gene expression. In turn, these proteins modify the expression of a large number of other proteins in the cell.

When Garraway’s team tested a number of these chromatin-based therapeutics in cancer cells together with traditional BRAF mutant melanoma drugs, the combination did appear to head off drug resistance and reduced the expression of the transcription factors that had been driving resistance. The treatment has yet to be tested clinically, but if its inhibitory effects bear out, the therapy could potentially be used not only to treat BRAF mutant melanoma, but other forms of melanoma that involve the same transcription factors as well.

Garraway, who is also an associate professor of medicine in the Department of Medical Oncology at the Dana-Farber Cancer Institute and at Harvard Medical School, said that the systematic approach his team used to probe the mechanisms underlying drug resistance in BRAF mutant melanoma can be applied to other forms of cancer, and is already being leveraged in other cancer types. The approach is not only comprehensive, but also relatively cost-effective. It is also not reliant on large quantities of cancer tumor samples, the collection of which can be a burden on patients.

"This method enables us to track drug resistance much more systematically,” he said. “If we can identify and understand the mechanisms underlying drug resistance, we are in a better position to identify clinically relevant resistance mechanisms. We are hopeful that this information will help us design new therapies and drug combinations that lead to more durable control of melanoma and eventually many other types of cancer.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Screen of Human Genome Reveals Set of Genes Essential for Cellular Viability
Using two complementary analytical approaches, scientists at Whitehead Institute and Broad Institute of MIT and Harvard have for the first time identified the universe of genes in the human genome essential for the survival and proliferation of human cell lines or cultured human cells.
Monday, October 19, 2015
GTEx: Useful Expression For Cancer Research
GTEx Project has recently published several papers reporting on findings from its two-year pilot phase.
Tuesday, May 26, 2015
In vivo CRISPR-Cas9 Screen Sheds Light On Cancer Metastasis And Tumor Evolution
Genome-scale study points to drivers of tumor evolution and metastasis, provides roadmap for future in vivo Cas9 screens.
Friday, March 06, 2015
Disorder in Gene-Control System is a Defining Characteristic of Cancer, Study Finds
Findings indicate that the disarray in the on-off mechanism is one of the defining characteristics of cancer.
Tuesday, December 23, 2014
Two Studies Identify A Detectable, Pre-Cancerous State In The Blood
Findings pave way for new lines of cancer research focused on detection and prevention.
Thursday, November 27, 2014
Dramatic Response And Resistance To Cancer Drug Traced
Sequencing reveals why thyroid tumor responded to, and eventually resisted, treatment.
Friday, October 10, 2014
Study Expands the Cancer Genomics Universe
The universe of cancer mutations is much bigger than previously thought, and key cancer genes are still to be discovered.
Tuesday, January 28, 2014
Study Finds Rules for Cancer Drivers
Any number of alterations to an individual’s genetic code has the potential to make a cell malfunction and proliferate into cancer tumors.
Monday, September 30, 2013
Broad Institute and Bayer Join Forces
The Broad Institute has entered into a strategic alliance with Bayer Healthcare in the area of oncogenomics and drug discovery.
Wednesday, September 11, 2013
Bringing Out the Usual – and Unusual – Cancer Genomics Suspects
Several years ago, researchers sequencing lung cancer genomes encountered a number of red herrings.
Tuesday, June 18, 2013
Chemical Screen Points to New Line of Attack Against Neuroblastoma
In the war on neuroblastoma, the current chemical weaponry is reaching its limit.
Monday, June 10, 2013
ATARiS Informatics Platform Hits the Jackpot
ATARiS is one of several tools developed at the Broad Institute to precisely tune in to the signals within noisy datasets.
Wednesday, May 22, 2013
Researchers Unearth New Clues About How Prostate Cancer Evolved
With the help of a computational model, Broad researchers were able to reconstruct the genomes of prostate cancer cells.
Thursday, May 16, 2013
Endometrial Cancer Findings Emerge from Genome Sequencing Study
Novel tumor sub-types have been identified that could lead to better risk stratification and more individualized and targeted treatments.
Friday, May 10, 2013
Delivering on a Promise: Nanoparticles Carry siRNA to Tumours
RNA interference, a gene-silencing phenomenon discovered in the late 1990s, was hailed for its potential as a treatment in cancer and other diseases.
Friday, September 21, 2012
Scientific News
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
RNA-Based Drugs Give More Control Over Gene Editing
CRISPR/Cas9 gene editing technique can be transiently activated and inactivated using RNA-based drugs, giving researchers more precise control in correcting and inactivating genes.
University of Glasgow Researchers Make An Impact in 60 Seconds
Early-career researchers were invited to submit an engaging, dynamic and compelling 60 second video illuminating an aspect of their research.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Dead Bacteria to Kill Colorectal Cancer
Scientists from Nanyang Technological University (NTU Singapore) have successfully used dead bacteria to kill colorectal cancer cells.
CRISPR-Cas9 Gene Editing: Check Three Times, Cut Once
Two new studies from UC Berkeley should give scientists who use CRISPR-Cas9 for genome engineering greater confidence that they won’t inadvertently edit the wrong DNA.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos